{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[12,2,12,3],[13,2,13,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910881097603321"]
[null,null,"Titolo",null,"Acute Myeloid Leukemia in Children : Standard of Care and Future Perspectives / / edited by Daisuke Tomizawa, Edward Anders Kolb, Dirk Reinhardt"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024"]
[null,null,"ISBN",null,"9783031633669"]
[{"$nulls":4},"9783031633652"]
[null,null,"Edizione",null,"[1st ed. 2024.]"]
[null,null,"Descrizione fisica",null,"1 online resource (334 pages)"]
[null,null,"Collana",null,"Pediatric Oncology, , 2191-0812"]
[null,null,"Disciplina",null,"616.99419"]
[null,null,"Soggetti",null,"Hematology"]
[{"$nulls":4},"Oncology"]
[{"$nulls":4},"Pediatrics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Part-1: Epidemiology and Biology of Pediatric AML. Overview and Epidemiology of Pediatric AML -- Chromosomal and Genomic Alterations in Pediatric AML -- Germline Predisposition of Pediatric AML. Part-2: Diagnosis of pediatric AML. Diagnosis and Classifications of Pediatric AML -- Measurable Residual Disease Assessment in Pediatric AML. Part-3: Advances in Treatment of Pediatric AML. De Novo AML -- Extramedullary AML (CNS disease. non-CNS extramedullary disease. and myeloid sarcoma) -- Acute Promyelocytic Leukemia -- Myeloid Proliferations Associated with Down Syndrome (ML-DS. TAM) -- Myeloproliferative Disorders in Non-Down Syndrome Patients -- AML in Specific Age Groups (Infants. Adolescents and Young Adults) -- Myeloid Neoplasms Post Cytotoxic Therapy in Children -- Advanced MDS in Children -- Relapsed/Refractory AML in Children and Evolution of Novel Therapies -- Stem Cell Transplantation/Cellular and Immunotherapies -- Pediatric AML in Resource-Limited Countries. Part-4: Supportive Issues in Pediatric AML. Infection Management in Pediatric AML -- Cardiotoxicity in Pediatric AML -- Late effects in Pediatric AML Survivors."]
[null,null,null,"Sommario/riassunto","This book provides up-to-date information on key topics and issues in Pediatric Acute Myeloid Leukemia (AML), including the epidemiology, biology, diagnosis and treatment of particular forms of the disease, supportive care, and survivorship. The entire spectrum of clinical "]
[{"$nulls":4},"management on pediatric AML is covered with the aim of equipping readers with the latest knowledge relevant to clinical practice and research, based on enormous efforts made by cooperative clinical trial groups and consortia worldwide. Each chapter is written by internationally renowned authorities who have been selected for their expertise in the subjects discussed. This book will serve pediatric hematologists/oncologists, fellows, and residents both as a comprehensive source of information and as a quick reference. The book will also be of interest to pediatricians and general practitioners."]